2007; 1: issue 5
Changing the Paradigm: New Perspectives in the Treatment of Haematological Malignancies
Chair’s introduction
Emili Montserrat, Christos Emmanouilides
Progress and prognosis in chronic lymphocytic leukaemia
Stephan Stilgenbauer
Fludarabine plus cyclophosphamide combination: a new standard for first-line
therapy in chronic lymphocytic leukemia
Peter Hillmen
Consolidation therapy with alemtuzumab prolongs remission of chronic
lymphocytic leukaemia
Clemens-Martin Wendtner
Combination therapy with alemtuzumab: existing data and future studies
Robin Foà
The role of alemtuzumab in patients with p53 defects
Andrew Pettitt
Advances in the management of follicular lymphoma
Michele Ghielmini
Radioimmunotherapy in non-Hodgkin’s lymphoma: can it change
the course of the disease?
Timothy Illidge
Where does 90Y-ibritumomab tiuxetan radioimmunotherapy fit?
Selecting the right patient
Martin Bentz
United for success against non-Hodgkin’s lymphoma: role and responsibilities
of the nuclear medicine department
John Buscombe
Diffuse large B-cell lymphoma: the curable disease?
Michael Pfreundschuh
New strategies with 90Y-ibritumomab tiuxetan in diffuse large B-cell lymphoma
and mantle cell lymphoma
Franck Morschhauser
An update on 90Y-ibritumomab tiuxetan in autologous stem cell transplantation
Christian Gisselbrecht